Elan to Spin Out Drug Discovery into Neotope
By Cormac Sheridan
Tuesday, August 14, 2012
DUBLIN, Ireland Elan Corp. plc is hiving off its early stage neurology drug discovery activity into a new entity, Neotope Biosciences, which will begin life with $120 million to $130 million in cash and seek a listing on an as yet to be determined U.S. exchange.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.